What Is a Biofilm — and Why Does It Matter for Your Sinuses?

Dr. Franklyn Gergits, ENT

Short answer: A biofilm is a structured community of bacteria encased in a self-produced protective matrix — essentially a fortress that bacteria construct on the sinus lining to shield themselves from antibiotics and the immune system. Biofilms are present in the majority of patients with chronic rhinosinusitis undergoing surgery, are associated with more severe disease and worse outcomes, and are one of the most common reasons sinus infections fail to respond to repeated antibiotic courses. Standard oral antibiotics cannot adequately penetrate an established biofilm. Addressing biofilm requires a multi-mechanism approach — not simply a broader antibiotic.

What a Biofilm Actually Is

The word biofilm sounds technical, but the concept is straightforward. When bacteria colonize a surface — including the mucosal lining of your sinuses — they do not simply float freely. Under the right conditions, they anchor to the surface and begin producing a complex matrix of polysaccharides, proteins, and extracellular DNA. This matrix — the biofilm — surrounds the bacterial community and creates an environment that is fundamentally different from free-floating bacteria in several critical ways.

Inside the biofilm, bacteria communicate with each other through chemical signaling — a process called quorum sensing. They coordinate their behavior, share resources, and collectively regulate gene expression in ways that make them far more resistant to environmental threats than they would be individually. A 2026 review in Frontiers in Immunology describes biofilms as “sophisticated immune modulators that actively perpetuate mucosal dysbiosis” — meaning they do not just hide from the immune system, they actively manipulate it to their advantage.

Why Antibiotics Cannot Eliminate a Biofilm

This is the central clinical problem. When a patient takes an oral antibiotic for a sinus infection, the antibiotic reaches the sinus mucosa through the bloodstream — but the concentration that actually penetrates the biofilm matrix is a fraction of the systemic dose. The matrix acts as a diffusion barrier, slowing antibiotic penetration and allowing bacteria within the deeper layers of the biofilm to survive at concentrations that would kill free-floating bacteria. Critically, the minimum antibiotic concentration required to eradicate bacteria living inside a biofilm — called the minimum biofilm eradication concentration — is 100 to 1,000 times higher than the concentration required to kill the same bacteria floating freely. No oral antibiotic achieves those concentrations in the sinus tissue. This is not a drug potency problem. It is a delivery and penetration problem.

The most common biofilm-forming organisms identified in CRS patients are Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Haemophilus influenzae. S. aureus biofilm is particularly clinically significant — its metabolic activity correlates positively with eosinophil frequencies and overall disease severity, connecting biofilm to the broader inflammatory picture of chronic rhinosinusitis.

The result is predictable: the antibiotic suppresses the surface bacteria that are not protected by the biofilm. The patient feels better. The antibiotic course ends. The bacteria within the biofilm, which were never eliminated, re-emerge and repopulate the mucosal surface. The infection appears to return. In most cases it never fully went away — it was simply suppressed at the surface while the biofilm-protected population waited it out.

A 2025 scoping review in the Journal of Medical Microbiology confirmed that polymicrobial biofilms — biofilms containing multiple bacterial species — are common in CRS and that standard cultures frequently fail to detect the organisms driving the infection, because those organisms are protected within the biofilm and do not grow easily on standard culture media. A 2026 review in Frontiers in Immunology introduces an additional survival mechanism — bacterial “small colony variants” and intracellular “Trojan Horse” reservoirs that persist even after surgery and antimicrobial therapy, explaining why some patients relapse even when their FESS appears technically successful.

How We Approach Biofilm at SAWC

At the Sinus and Allergy Wellness Center of North Scottsdale, our approach to biofilm-driven sinusitis is built around three principles: identify the organisms, disrupt the biofilm through multiple mechanisms simultaneously, and deliver antibiotic therapy topically when indicated so the drug reaches the sinus mucosa directly rather than relying solely on systemic absorption.

Identify the organisms. We use molecular diagnostic testing through MicroGenDX — next-generation DNA sequencing of a directed sinus specimen — to identify the organisms actually present in the sinus, including those that would never grow on a standard culture plate because they are protected within a biofilm or present in low abundance. This tells us what we are actually treating before any antibiotic decision is made.

Disrupt the biofilm. Our biofilm rinse protocol combines three components that target the biofilm matrix through different mechanisms, based on the biological rationale of multi-mechanism disruption and emerging clinical data. Xylitol — which has the strongest clinical evidence among the components — inhibits biofilm formation and reduces biofilm biomass in studies against multiple organisms including S. aureus and P. aeruginosa, and is the only anti-biofilm therapy showing statistically significant reduction in symptom scores compared with placebo in more than one clinical trial. Diluted Johnson’s baby shampoo at one percent concentration demonstrated statistically significant biofilm reduction (p = 0.043) against S. aureus and P. aeruginosa in CRS specimens in a 2024 study — providing direct in vitro evidence for this component. Manuka honey has in vitro antimicrobial and biofilm-disrupting activity, killing 63 to 91 percent of MSSA, MRSA, and P. aeruginosa biofilms at effective concentrations, though large clinical trial evidence remains limited. Together these are added to the saline rinse and delivered directly to the sinus mucosa through high-volume irrigation.

Targeted topical antibiotic therapy. For selected patients with recalcitrant or post-surgical disease and a culture-positive result, the appropriate antibiotic can be added directly to the nasal rinse — delivering it to the sinus mucosa at concentrations far higher than systemic dosing achieves, and bypassing the gut absorption that limits systemic antibiotic penetration into the sinuses. A 2026 multi-site study of difficult-to-treat post-surgical CRS patients found that large-volume topical antibiotic irrigations achieved 62.7 percent infection clearance at eight weeks with significant improvement in sinus symptom scores. Mupirocin, tobramycin, and gentamicin are the most commonly used agents in this setting. This approach is most supported by the evidence in cases involving S. aureus and other recalcitrant organisms.

Why This Matters for Patients Who Have Failed Multiple Antibiotics

For patients in Scottsdale, Phoenix, and the greater Maricopa County area who have been through two, three, or five antibiotic courses for chronic sinus infections — the biofilm question is one of the first things I consider. Not because it is always the answer, but because it explains a pattern that the standard antibiotic-cycle approach never addresses. Recurrent sinus infections after multiple antibiotic courses are almost never a prescribing problem. They are almost always a diagnostic problem. The organism has not been identified. The biofilm has not been disrupted. And treatment matched to the actual situation — not the assumed one — has not been tried.

Want to Understand More?

This post is part of the Why Sinus Treatments Fail — And What Starts Before Them series on the Airway & Sinus Wellness Review.

→ Why Antibiotics Keep Failing Your Sinus Infection

→ What Is MicroGenDX — and Why Does It Change How We Treat Sinus Infections?

→ Why Do I Keep Getting Sinus Infections After Surgery?

→ Does Balloon Sinuplasty Actually Work?

→ Airway & Sinus Wellness Review — Full Publication

This post is part of the Why Sinus Treatments Fail — And What Starts Before Them section of the Airway & Sinus Wellness Review.

References

1. Tan S, Lai J, Yu S. Biofilm adaptation and mucosal immune dysregulation in recalcitrant chronic rhinosinusitis: from pathogenesis to a therapeutic roadmap. Frontiers in Immunology. 2026. Biofilms as “sophisticated immune modulators that actively perpetuate mucosal dysbiosis.”

2. Broderick D, Biswas K, Kim R, Douglas R. Polymicrobial biofilms in chronic rhinosinusitis: a scoping review. Journal of Medical Microbiology. 2025. Standard cultures miss biofilm-protected organisms; polymicrobial biofilms common in CRS.

3. Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2014. Biofilm prevalence in surgical CRS patients; association with worse outcomes.

4. Piccirillo JF, Payne SC, Rosenfeld RM, et al. Clinical Practice Guideline: Adult Sinusitis Update. Otolaryngology–Head and Neck Surgery. 2025. entnet.org

5. Karunasagar A, Jalastagi R, Naik A, Rai P. Detection of bacteria by 16S rRNA PCR and sequencing in culture-negative chronic rhinosinusitis. The Laryngoscope. 2018. NGS identifies organisms missed by standard culture in biofilm-driven CRS.

6. Gergits FR. Posterior Sinonasal Syndrome (PSS). Preprint DOI: 10.20944/preprints202603.0858.v1. ORCID: 0009-0000-4893-6332.

7. Sabino HA, et al. Biofilm-forming bacteria from CRS: MBEC 100–1,000x higher than planktonic MIC; 20% of planktonic-susceptible bacteria produce antibiotic-tolerant biofilms. Otolaryngology–Head and Neck Surgery. 2022.

8. Zahedi et al. Diluted 1% baby shampoo produced statistically significant biofilm reduction (p=0.043) against S. aureus and P. aeruginosa in CRSwNP specimens. 2024.

9. Multi-site topical antibiotic irrigation study. Large-volume topical antibiotic irrigations: 62.7% infection clearance at 8 weeks; significant SNOT-22 improvement (34.8 → 21.8). Most common agents: mupirocin, tobramycin, gentamicin. International Forum of Allergy & Rhinology. 2026.

10. Huang CF, et al. Common biofilm-forming organisms in CRS: S. epidermidis (34%), S. aureus (28%), P. aeruginosa (8%), S. pneumoniae (6%), H. influenzae. Quorum sensing and biofilm structure drive antibiotic resistance. 2022.

About the Author

Dr. Franklyn R. Gergits, MBA, DO, FAOCO is a Board-Certified Otolaryngologist and Fellowship-Trained Otolaryngic Allergist with a Clinical Focus in Rhinology and Airway Disorders and over 30 years of clinical experience. He is the founder of the Sinus & Allergy Wellness Center of North Scottsdale, where he performs in-office balloon sinuplasty, turbinate reduction, NEUROMARK® posterior nasal nerve ablation, and Eustachian tube dilation under local anesthesia. He performed the first balloon sinuplasty in Pennsylvania and holds dual Entellus Centers of Excellence certifications. Dr. Gergits is the originator of the Posterior Sinonasal Syndrome (PSS) hypothesis — a clinical framework identifying pepsin-mediated posterior nasal mucosal injury as an upstream driver of chronic rhinosinusitis. Preprint available at Preprints.org (DOI: 10.20944/preprints202603.0858.v1). ORCID: 0009-0000-4893-6332.

SinusAndAllergyWellnessCenter.com · 480-525-8999

This content is for educational purposes only and does not constitute medical advice. If you have experienced repeated antibiotic failures for sinus infections, consult with a qualified otolaryngologist for a complete evaluation including consideration of biofilm-directed therapy.